Operational Highlights and Financial Results for the Year Ended June 30, 2021
August 30, 2021 19:38 ET
|
Mesoblast Limited
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
Mesoblast Corporate Update and Financial Results Webcast
August 30, 2021 08:00 ET
|
Mesoblast Limited
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Appendix 4C Quarterly Activity Report
July 29, 2021 20:06 ET
|
Mesoblast Limited
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its...
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
July 18, 2021 20:58 ET
|
Mesoblast Limited
NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes...
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
July 15, 2021 20:15 ET
|
Mesoblast Limited
NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from...
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
June 30, 2021 19:46 ET
|
Mesoblast Limited
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...
Operational Highlights and Financial Results for the Period Ended March 31, 2021
June 02, 2021 20:01 ET
|
Mesoblast Limited
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
Mesoblast Corporate Update and Financial Results Webcast
June 02, 2021 18:01 ET
|
Mesoblast Limited
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss...
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
May 25, 2021 07:00 ET
|
Mesoblast Limited
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed...
Appendix 4C Quarterly Activity Report
April 29, 2021 20:47 ET
|
Mesoblast Limited
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its...